Axsome Therapeutics (NASDAQ:AXSM) Insider Sells $1,383,300.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) insider Ari Maizel sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total value of $1,383,300.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Axsome Therapeutics Trading Down 0.5%

Shares of NASDAQ AXSM opened at $185.96 on Monday. The company has a market cap of $9.37 billion, a price-to-earnings ratio of -39.82, a price-to-earnings-growth ratio of 9.80 and a beta of 0.44. Axsome Therapeutics, Inc. has a 12-month low of $86.99 and a 12-month high of $191.50. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The stock’s 50 day simple moving average is $159.39 and its 200 day simple moving average is $133.42.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. The business’s quarterly revenue was up 63.2% on a year-over-year basis. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after buying an additional 609,516 shares in the last quarter. Norges Bank acquired a new position in Axsome Therapeutics during the second quarter worth about $48,889,000. Invesco Ltd. raised its position in Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after acquiring an additional 419,008 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock valued at $46,662,000 after acquiring an additional 399,000 shares during the last quarter. Finally, Hood River Capital Management LLC acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at about $38,740,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Analyst Ratings Changes

Several analysts recently weighed in on AXSM shares. Guggenheim reiterated a “buy” rating and issued a $205.00 price objective on shares of Axsome Therapeutics in a research report on Friday, January 2nd. Royal Bank Of Canada boosted their price objective on Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. Morgan Stanley downgraded Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a research note on Thursday, January 8th. Finally, Piper Sandler increased their price target on Axsome Therapeutics from $148.00 to $223.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $203.17.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.